Table 1 The characteristics of all studies
Study | Year | No. of participants | Study design | Setting | Etiology of CS | Quality assessment |
|---|---|---|---|---|---|---|
ECMO plus IABP vs. IABP | ||||||
 Perazzolo Marra et al. | 2013 | 35 | Obs | Europe | AMI | 5 |
 Tsao et al. | 2012 | 58 | Obs | Asia | AMI | 7 |
 Sheu et al. | 2010 | 219 | Obs | Asia | STEMI | 9 |
PLVADs vs IABP | ||||||
 Seyfarth et al. (ISAR-SHOCK) | 2008 | 26 | RCT | Europe | AMI | 7 |
 Schrage et al | 2018 | 352 | Obs | Europe | AMI | 9 |
 Bochaton et al | 2019 | 13 | RCT | Europe | AMI | 4 |
 Dagmar et al. (IMPRESS trial) | 2016 | 48 | RCT | Europe | AMI | 7 |
Shah et al | 2012 | 27 | Obs | United States | STEMI or UA/NSTEMI | 6 |
 Thiele et al | 2005 | 41 | RCT | Europe | AMI | 7 |
 Manzo-Silberman et al. | 2013 | 78 | Obs | Europe | ACS | 9 |
 Burkhoff et al. | 2006 | 33 | RCT | United States, Europe | AMI (70%) | 5 |
 Schwartz et al. | 2012 | 76 | Obs | United States | STEMI (68%) | 7 |
ECMO plus IABP vs. ECMO | ||||||
 Park et al. | 2014 | 96 | Obs | Asia | AMI | 8 |
 Chung et al. | 2011 | 20 | Obs | Asia | AMI | 5 |
 Aoyama et al. | 2014 | 38 | Obs | Asia | AMI, INCA (2 pts, OHCA 7 pts) | 6 |
PLVAD vs. medical therapy | ||||||
 Feistritzer et al. | 2020 | 1024 | RCT | Europe | AMI | 7 |
IABP vs medical therapy | ||||||
 Sanborn et al. (SHOCK Registry) | 2000 | 383 | Obs | United States, Canada, Europe, New Zealand | AMI | 9 |
 Anderson et al. (GUSTO-I) | 1997 | 310 | Obs | United States, Europe | STEMI | 9 |
 Barron et al. (NRMI-2) | 2001 | 2990 | Obs | United States | AMI | 8 |
 Gu et al | 2010 | 91 | Obs | Asia | STEMI | 5 |
 Prondzinsky et al. (IABP-SHOCK) | 2010 | 40 | RCT | Europe | AMI | 7 |
 Zeymer et al. (Euro Heart Survey PCI) | 2012 | 653 | Obs | Europe | STEMI or NSTEMI | 8 |
 Dziewierz et al. (EUROTRANSFER registry) | 2014 | 51 | Obs | Europe | STEMI | 5 |
 Brunner et al. | 2019 | 42 | Obs | Europe | AMI | 5 |
 Thiele et al. (IABP-SCHOCK II) | 2012 | 598 | RCT | Europe | AMI | 7 |
 Kim et al. (KAMIR) | 2015 | 1214 | Obs | Asia | AMI | 8 |
ECMELLA vs. Impella | ||||||
 Castro et al. | 2020 | 27 | Obs | Europe | ICMP(53.3%), DCM (26.7%) | 6 |
ECMELLA vs. ECMO | ||||||
 Pappalardo et al. | 2016 | 63 | Obs | Europe | STEMI (54%) | 9 |
 PATEL et al | 2019 | 66 | Obs | United States | STEMI (32%), NSTEMI (14%) | 6 |
 Tepper et al | 2016 | 45 | Obs | United States | AMI (26%), PCS (28%) | 7 |
 Schrage et al. (STOP-SHOCK) | 2020 | 510 | Obs | Europe | AMI (63%) | 9 |
 MOURAD et al | 2018 | 16 | Obs | Europe | AMI | 5 |
 AKANNI et al | 2019 | 225 | Obs | United States | AMI (25.78%), PCS (36.44%) | 6 |
ECMO vs. Impella | ||||||
 Wernly et al | 2021 | 149 | Obs | Europe | AMI (51%) | 8 |
 Lamarche et al | 2010 | 61 | Obs | Europe | ACS (39.3%) | 8 |
 Lemor et al. | 2020 | 900 | Obs | United States | AMI | 7 |
 Karami et al. | 2020 | 128 | Obs | Europe | AMI | 8 |
 Karatolios et al. | 2020 | 166 | Obs | Europe | AMI (86%) | 8 |
ECMO plus IABP vs. PLVADs | ||||||
 Kagawa et al. | 2012 | 73 | Obs | Asia | ACS, INCA, OHCA | 9 |